Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2007-5-1
pubmed:abstractText
Imatinib mesylate treatment causes remissions in a majority of patients with chronic myeloid leukemia (CML), but relapses are an increasing problem. We hypothesized that imatinib-resistant leukemic cells emerge from CML stem cells that acquire BCR-ABL gene mutations even before exposure to BCR-ABL-targeted agents such as imatinib.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1460-2105
pubmed:author
pubmed:issnType
Electronic
pubmed:day
2
pubmed:volume
99
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
680-93
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:17470736-Colony-Forming Units Assay, pubmed-meshheading:17470736-DNA Mutational Analysis, pubmed-meshheading:17470736-DNA Primers, pubmed-meshheading:17470736-Genes, abl, pubmed-meshheading:17470736-Genomic Instability, pubmed-meshheading:17470736-Humans, pubmed-meshheading:17470736-Immunomagnetic Separation, pubmed-meshheading:17470736-In Situ Hybridization, Fluorescence, pubmed-meshheading:17470736-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:17470736-Leukocyte Count, pubmed-meshheading:17470736-Mutation, pubmed-meshheading:17470736-Piperazines, pubmed-meshheading:17470736-Protein Kinase Inhibitors, pubmed-meshheading:17470736-Pyrimidines, pubmed-meshheading:17470736-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:17470736-Stem Cells, pubmed-meshheading:17470736-Tumor Cells, Cultured
pubmed:year
2007
pubmed:articleTitle
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
pubmed:affiliation
Terry Fox Laboratory, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC, V5Z 1L3, Canada. xjiang@bccrc.ca
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural